Trimetazidine restores autophagy via lncRNA H19/AMPK in diabetic heart: Implications for its therapeutic value against diabetic cardiomyopathy

Objective Previous studies have shown that trimetazidine (TMZ) alleviates diabetes‐induced cardiac dysfunction. However, the underlying mechanism for its protective effects on cardiac function remains incompletely understood. Diminished autophagy was found in diabetic hearts, and restoration of auto...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical and experimental pharmacology & physiology 2025-01, Vol.52 (1), p.e70006-n/a
Hauptverfasser:	Wei, Wei, Hu, Yadi, Gao, Jing, Fan, Danjun, Ye, Xiaorong, Chen, Yan
Format:	Artikel
Sprache:	eng
Schlagworte:	AMP-Activated Protein Kinases - metabolism Animals Autophagy Autophagy - drug effects Cardiac function Cardiomyocytes Cardiomyopathy Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Experimental - drug therapy Diabetes Mellitus, Experimental - metabolism Diabetic Cardiomyopathies - drug therapy Diabetic Cardiomyopathies - genetics Diabetic Cardiomyopathies - metabolism Diabetic Cardiomyopathies - pathology Heart diseases High fat diet LncRNA H19 Low fat diet Male Mice Mice, Inbred C57BL Myocytes, Cardiac - drug effects Myocytes, Cardiac - metabolism Myocytes, Cardiac - pathology Neonates Non-coding RNA Nutrient deficiency Palmitic acid Rats RNA, Long Noncoding - genetics RNA, Long Noncoding - metabolism Streptozocin Trimetazidine Trimetazidine - pharmacology Trimetazidine - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!